Cancer

News

TAE raises $40m to develop new targeted radiotherapy

Medtech firm TAE Life Sciences is developing a ground-breaking radiotherapy technology which will be able to treat hard-to-reach cancers with targeted beams.

Events

Partner Content

Personalized and Precision Medicine International Conference...

Int. Conference on Personalized and Precision Medicine

News

Merck shows canny cancer strategy in $5.76bn Eisai milestone...

Firms will co-develop Lenvima and Keytruda combinations

News

Novartis expands virtual clinical trial project with Science...

Swiss pharma builds on existing collaboration with Science 37

News

Celgene to tackle 'undruggable' targets with Vividion

Celgene has signed a deal with Vividion Therapeutics to develop drugs for oncology, inflammatory, and neurodegenerative diseases.

News

A NICE yes for latest immunotherapy Bavencio

NICE has recommended Merck KGaA and Pfizer’s Bavencio in previously treated metastatic Merkel Cell Carcinoma, a rare and aggressive form of skin cancer.

TAE raises $40m to develop new targeted radiotherapy

Personalized and Precision Medicine International Conference...

Merck shows canny cancer strategy in $5.76bn Eisai milestone...

Novartis expands virtual clinical trial project with Science...

Celgene to tackle 'undruggable' targets with Vividion

A NICE yes for latest immunotherapy Bavencio

EU clears first drug therapy for rare disease cALD

Discover a new era of healthcare panel engagement: Grounded ...

Cancer

Editor's Picks